![Birgit Kjældgaard Giwercman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Birgit Kjældgaard Giwercman
Amministratore Delegato presso BKG Pharma ApS
Posizioni attive di Birgit Kjældgaard Giwercman
Società | Posizione | Inizio | Fine |
---|---|---|---|
BKG Pharma ApS
![]() BKG Pharma ApS Pharmaceuticals: MajorHealth Technology BKG Pharma ApS develops and commercializes novel antibiotics against multidrug-resistant bacteria. It conducts research and development on treatment for multi-resistant infections such as resistance to chemotherapy. The company was founded by Birgit K. Giwercman in 2004 and is headquartered in Copenhagen, Denmark. | Fondatore | 15/03/2010 | - |
Amministratore Delegato | 15/03/2010 | - | |
Direttore/Membro del Consiglio | 01/01/2004 | - | |
BKG Vet Pharma ApS | Amministratore Delegato | 01/01/2011 | - |
Storia della carriera di Birgit Kjældgaard Giwercman
Precedenti posizioni note di Birgit Kjældgaard Giwercman
Società | Posizione | Inizio | Fine |
---|---|---|---|
Pantheco A/S
![]() Pantheco A/S Pharmaceuticals: MajorHealth Technology Pantheco A/S is a Danish biotech company, whose mission it is to develop drugs based upon Peptide Nucleic Acid (PNA) for the treatment of infectious diseases caused by resistant microorganisms. Pantheco represents a spin-off of the research activities and know-how within the Peptide Nucleic Acid (PNA) antisense technology invented at University of Copenhagen in 1992 and the PNA Patent Rights licensed from Isis Pharmaceuticals, Inc. in US. By employing the PNA technology, chemistry, know-how, and the exclusive rights for human therapeutic uses within anti-infectives, Pantheco has the unique opportunity to generate novel classes of anti-infective drugs and become a world class leader within novel generations of antisense therapeutics. | Direttore/Membro del Consiglio | - | - |
Cureon A/S
![]() Cureon A/S Pharmaceuticals: MajorHealth Technology Cureon A/S is a Danish biotech company that owns the pharmaceutical rights to a novel DNA analogue, termed LNA (Locked Nucleic Acid) which displays unprecedented affinity compared to all other DNA chemistries. The company believes that the unique properties of this novel analogue will enable oligonucleotide based therapeutics (Antisense therapy) to enter main-stream pharmaceuticals. | Direttore/Membro del Consiglio | - | - |
University of Copenhagen | Corporate Officer/Principal | - | - |
Formazione di Birgit Kjældgaard Giwercman
University of Copenhagen | Doctorate Degree |
Statistiche
Distribuzione geografica
Danimarca | 6 |
Posizioni
Director/Board Member | 3 |
Chief Executive Officer | 2 |
Founder | 1 |
Settori
Health Technology | 4 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Pantheco A/S
![]() Pantheco A/S Pharmaceuticals: MajorHealth Technology Pantheco A/S is a Danish biotech company, whose mission it is to develop drugs based upon Peptide Nucleic Acid (PNA) for the treatment of infectious diseases caused by resistant microorganisms. Pantheco represents a spin-off of the research activities and know-how within the Peptide Nucleic Acid (PNA) antisense technology invented at University of Copenhagen in 1992 and the PNA Patent Rights licensed from Isis Pharmaceuticals, Inc. in US. By employing the PNA technology, chemistry, know-how, and the exclusive rights for human therapeutic uses within anti-infectives, Pantheco has the unique opportunity to generate novel classes of anti-infective drugs and become a world class leader within novel generations of antisense therapeutics. | Health Technology |
Cureon A/S
![]() Cureon A/S Pharmaceuticals: MajorHealth Technology Cureon A/S is a Danish biotech company that owns the pharmaceutical rights to a novel DNA analogue, termed LNA (Locked Nucleic Acid) which displays unprecedented affinity compared to all other DNA chemistries. The company believes that the unique properties of this novel analogue will enable oligonucleotide based therapeutics (Antisense therapy) to enter main-stream pharmaceuticals. | Health Technology |
BKG Pharma ApS
![]() BKG Pharma ApS Pharmaceuticals: MajorHealth Technology BKG Pharma ApS develops and commercializes novel antibiotics against multidrug-resistant bacteria. It conducts research and development on treatment for multi-resistant infections such as resistance to chemotherapy. The company was founded by Birgit K. Giwercman in 2004 and is headquartered in Copenhagen, Denmark. | Health Technology |
BKG Vet Pharma ApS |